New treatments and new drugs for avian influenza virus (AIV) infection are developed continually, but there are still high mortality rates. The main reason may be that not all cell death pathways induced by AIV were blocked by the current therapies. In this review, drugs for AIV and associated acute respiratory distress syndrome (ARDS) are summarized. The roles of antioxidant (vitamin C) and multiple immunomodulators (such as Celecoxib, Mesalazine and Eritoran) are discussed. The clinical care of ARDS may result in ischemia reperfusion injury to poorly ventilated alveolar cells. Cyclosporin A should effectively inhibit this kind of damages and, therefore, may be the key drug for the survival of patients with virus-induced ARDS. Treatment with protease inhibitor Ulinastatin could also protect lysosome integrity after the infection. Through these analyses, a large drug combination is proposed, which may hypothetically greatly reduce the mortality rate. 

**Facts**
- The infection of avian influenza induces reactive oxygen species accumulation, causing hyperimmune response to the virus, which may have adverse effects on vital organs and result in high pathogenicity and mortality.
- Clinical care of acute respiratory distress syndrome may result in ischemia reperfusion injury to alveolar cells that are poorly ventilated or poorly supplied with blood. The main mechanism includes mitochondrial permeability transition and the release of apoptotic mediators.
- Combinations of immunomodulators and antiviral agents significantly reduced mortality in mice infected with the avian influenza virus (AIV). However, the reduced mortality rate was still relatively high (over 10%).
- Virus neuraminidase digests lysosomal membrane glycoproteins, which induces lysosome lysis and the release of lysosomal proteases. This is another mechanism of AIV-induced cell death.

**Open Questions**
- New treatments and new drugs for avian influenza are developed continually; then why is there still such a high mortality rate?
- Why did acute respiratory distress syndrome clinical cares enable the survival of only partially AIV-infected patients, whereas the others died?
- Can immunomodulators and antiviral agents completely cure AIV infection?
- Is there a hope of reducing the mortality rate to below 1% (as is the case of the ordinary influenza)?

Over the last decade, an endless stream of severe acute respiratory syndrome (SARS), influenza (H1N1, H5N1, H7N9) and associated malignant respiratory diseases have emerged, which threatens the human health seriously. Because of their high mortality rate and infectious nature, these diseases usually cause psychological panic among the public that is more serious than the diseases themselves. As reported on 10 May 2013, of the 111 patients we studied 76.6% were admitted to an intensive care unit and 27.0% died. New treatments and new drugs for avian influenza are developed continually, then why is there such a high mortality rate? We have to introspect about our current therapies for avian influenza and develop a better one. In this review, therapeutic uses of the drugs for avian influenza and associated pneumonia are summarized. In general, conventional therapies using only antiviral drugs resulted in 50–80% mortality rate, whereas the new therapies with antiviral drugs and immunomodulators reduced the mortality rate to 10–50%. However, this was still a high ratio. The main reason may be that not all cell death pathways induced by the AIV were blocked by the therapies (Figure 1). At the end of this review, a large reagent combination is proposed, which may greatly reduce the mortality rate prospectively.
The symptoms of H7N9 infection, that is, the upper respiratory tract infection, is not very heavy with mild cough, which does not attach attention to the majority of the patients. However, the disease progresses very quickly. Ten days post infection, pulmonary symptom appears immediately (pneumophila). Next, the condition involves the proliferation of both lungs, serious lung exudation and low pulmonary oxygenation (low oxygenated blood). A patient without effective treatments at that time will develop acute respiratory distress syndrome (ARDS) and may die a few days later.2 Symptoms of other types of avian influenza and SARS are almost the same. Hence, the key to survival of the patients may be not only the suppression of the virus but also the controlled inflammatory response of the hosts.

The SARS mortality statistics published by World Health Organization in 2003 showed that the overall average mortality rate was about 15%, but the mortality rate of young people with strong immunity was much higher than that of old people with weak immunity.3 For H5N1, the overall mortality rate was about 56%. However, the youth group (10–19 years old individuals) got the highest mortality rate of 73% and the mortality rate for people over 50 years was only 18%.4 Moreover, H1N1 deaths mostly occur in middle-aged adults and the severity of the H1N1 cases was by far higher in the 18–50 years age group, contrary to seasonal influenza where fatality occurs most often in the elderly people (> 65 years old), with an overall mortality rate being < 1%.5 Some researchers believe that the infection of avian influenza causes multiple complications in the patient, resulting in multi-organ failure, and may be related to the hyperimmune response to the virus, which may have adverse effects on vital organs and result in high pathogenicity and mortality.6–9 The H5N1 virus may set off a cytokine storm, for example, interferon (IFN)-inducible protein IP-10, IFN-β, chemokines, interleukin-6 (IL-6) and so on. This cytokine outbreak is likely to lead to cell death.5–9 These data may suggest that healthy young people would become the main target of H5N1 attack. In other words, the stronger the immune system, the more severe the inflammatory response after the infection, and, thus, the higher risk of death. AIV does not kill us, but we may be killed by ourselves. For the newborn virus H7N9, no such full-scale statistics is available now. Nevertheless, from its high mortality rate and rapid disease progression,1,2 a similar cytokine burst with an excessive immune response can be expected (cytokine burst in the H7N9 patient has been proved recently).10,11

Antioxidant

Reactive oxygen species (ROS) have a crucial role in inflammatory response.12 Aggregation of neutrophils at pulmonary alveoli activate and release the oxygen-free radicals, proteases and lipid peroxide, resulting in injuries to the pulmonary microvascular membrane and alveolar epithelial membrane, and the subsequent pulmonary edema and ARDS. The activated neutrophils generate ROS exponentially (over 10 times the rate in the resting cell). The oxidative injuries include the following: (i) lipid peroxidation and detriments to structures and functions of the cell membrane and the organelle membrane; (ii) enzyme inactivation; (iii) inactivation of protease inhibitors and release of lysosomal proteases; and (iv) working on blood plasma to induce strong chemoattractants, causing more neutrophil aggregation, more ROS production and subsequently more severe lung injury.12 Thus, ROS form a positive feedback loop (they could be self-amplified).

Among all ROS scavengers, ascorbic acid (vitamin C (VC)) is the best choice, as it is effective, non-toxic, easy to be absorbed and more stable than the others (similar to reduced glutathione). VC scavenges ROS through a non-enzymatic process.13 In the nineteenth century, VC had been used to treat hepatitis, encephalitis, influenza, SARS and some other viral diseases.13 In 1970, Nobel laureate chemist Linus Pauling published the book ‘Vitamin C And The Common Cold’, wherein he advocated that high doses of VC can prevent and treat colds.14

There is little direct evidence to show that the high amounts of VC would be helpful for patients during a severe avian influenza infection. However, an investigation showed that in several publicized locations, including Vietnam, many (about 50%) of the humans infected with avian flu (H5N1) did not die.15 Ely16 suggested that their survival may have occurred, as the particular viral load constituting their moderate infection may have been small enough that the
VC they accidentally acquired from their diets was adequate to defend them.

There are about 4000 species of ‘normal’ mammals that synthesize VC, on average ~50 mg/kg body weight daily or about 5 g/day (normalized to 70 kg for a human). This amount has been found to be essential for optimum health and resistance to many diseases. In summary, from a large number of studies, we know that effective inhibition of viral replication and apparent symptom alleviation usually requires over 5 mM of VC (about 4.4 g for about 5 l of human blood). However, the general oral dosage of VC tablets is 100–300 mg daily, which is much lower than the dose required for influenza treatment. For higher absorption efficiency, and considering that over 1 g of VC by oral administration may cause diarrhea, nausea, vomiting, stomach cramps and other side effects, the injection approach could be adopted for those patients infected with avian influenza. In addition, long-term use of high-dose VC (>2–3 g/day) causes scurvy after abrupt stopping. Thus, the VC injection should be reduced gradually during recovery but not stopped abruptly.

When most patients were identified to be infected by AIV and have been sick for a couple of days, pulmonary symptoms started to develop. Their alveolar cells may be already damaged. Therefore, their risks to develop acute respiratory failure were very high. Timely pretreatment with VC before diagnosis in the hospital may be very important for the patient to avoid lethal inflammation.

**Protectant of Mitochondrial Membrane Permeability**

Simply providing humans with 50 mg/kg body weight of VC in one or few doses (oral or other) on a fixed schedule will not replicate the sufficiency seen in normal mammals. Mice and birds can synthesize considerable amounts of VC, but they can be still infected by avian influenza. Therefore, additional treatments other than ROS scavengers have been applied. For the avian-influenza-infected patient with pneumonia, continuous increase of alveolar/capillary membrane permeability is the most common damage. Mitochondria have a critical role in mediating calcium overload and oxidative damage (e.g., hydrogen peroxide)-induced cell death, such as ischemia reperfusion (IR) injury. The mitochondrial permeability transition (mPT) after this injury leads to mitochondrial swelling, outer membrane rupture and the release of apoptotic mediators (such as cytochrome c). The mPT pore is thought to consist of the adenine nucleotide translocator, a voltage-dependent anion channel and cyclophilin D. Cyclosporin A (CsA) can effectively inhibit cyclophilin D and, therefore, it protects myocardial cells form IR injury (such as myocardial infarction). H1N1 infection inactivated the cellular catalase, thus leading to the accumulation of ROS (mainly hydrogen peroxide), whereas H5N1 induced extracellular calcium influx, leading to apoptosis. ROS accumulation, extracellular calcium influx and the accompanying mitochondrial damages were also found in hypoxemia patient’s lung cells. Thus, ROS accumulation (especially hydrogen peroxide) and calcium influx may be the common injury factors for both IR injuries and ARDS damages. CsA may have a protective effect on such damages caused by the avian influenza infection.

Clinical care of ARDS may result in IR injury of alveolar cells that are poorly ventilated or poorly supplied with blood. Avian-influenza-infected patients often develop the hypoxic pulmonary vasoconstriction (HPV), which is an essential physiological mechanism of the lung that directs blood perfusion from poorly ventilated to well-ventilated lung areas, to optimize gas exchange. But HPV development may cause mismatched blood flow and alveolar ventilation, and may result in life-threatening hypoxemia. Some ARDS clinical cares are usually carried out at this time, for example, mechanical ventilation, high-flow oxygen therapy, corticosteroid treatment and inhaled nitric oxide administration. However, these treatments may restore the blood and oxygen supply to the poorly ventilated alveolar cells. In case of a mismatch of blood flow and alveolar ventilation, corticosteroid treatment and inhaled nitric oxide administration may restore the blood supply to the poorly supplied but well-ventilated alveolar cells. For both the conditions, IR injury or similar damages may occur (Figure 1). In other words, more severe cell death may happen after the ARDS clinical management, but not at the time of occurrences of HPV or hypoxemia. CsA effectively inhibit this kind of damage and therefore may be the key drug for the survival of ARDS patients.

Nevertheless, CsA-treated cells are not protected from Bax (B-cell lymphoma 2 (Bcl-2)-associated X protein) or tumor necrosis factor-α (TNFα)-induced mitochondrial dysfunction and cell death. Although H5N1 and H1N1 viruses dramatically induced the TNFα factor in alveolar macrophages, TNFα activates both an apoptotic pathway (i.e., TRADD, RIP and JNK) and a survival pathway mediated by NF-κB transcription of survival genes. ROS accumulation triggers a signal to facilitate the TNFα apoptotic pathway. Balance between the pro-apoptotic factor Bax and the anti-apoptotic members of the Bcl-2 family is regulated by the cellular redox status. A tilt in favor of the superoxide abets cell survival and proliferation. On the contrary, a tilt towards hydrogen peroxide generates an intracellular milieu permissive of death execution. Thereby, a high dose of VC as an antioxidant (mainly scavenging hydrogen peroxide) may block both TNFα- and Bax-induced apoptosis (Figure 3). Rapamycin regulates Bcl-2 and TNFα levels too, but it may exacerbate the H5N1-induced autophagy, which may lead to more severe cell death. Thus, Rapamycin may not be suitable for the treatment of AIV infection.

**Immunomodulators**

CsA also inhibits calcineurin activity. Calcineurin is a key enzyme in T-cell activation, which can stimulate the transcription of NF-AT (T-cell-specific transcription factor) and NF-IL-2A (IL-2 promoter elements). Thus, CsA blocks the activation of T cells and suppresses the generation of a variety of cytokines, such as IL-2 and IFNs. CsA could not be replaced by FK506, because CsA works not only as an immunosuppressant (similar to FK506) but also as a...
protectant for maintaining the integrity of the mitochondrial membrane.18 Nevertheless, many side effects were found for CsA, for example, renal tubular toxicity and vascular–interstitial lesions. Thus, its substitutes (some small-molecule chemical compounds) have been developed recently, such as Debio-025 and GW5.34,35 However, none of them has been used clinically so far. CsA only shows its apparent side effects after a long-term use (usually over a year).36 Hence, for the current AIV therapy (usually within a month), CsA could be used expediently.

Szretter et al.37 showed that IFNα/β pretreatment significantly reduced the replication of the H5N1 virus. Zheng et al.26 indicated that combinations of immunomodulators and antiviral agents significantly reduced mortality in mice infected by a high inoculum of influenza H5N1 virus. They used two immunomodulators – Celecoxib (cyclooxygenase-2 inhibitor) and Mesalazine (5-amino salicylic acid). These two drugs did not cause significant immunosuppression and, hence, hardly influenced the body’s immune system against AIV.26 Six of the eight cytokines induced by H5N1 and H1N1 (IL-6, IFNα, macrophage inflammatory protein-1β, IFNγ-induced protein 10, regulated on activation normal T cell expressed and secreted, and monocyte chemotactic protein 1) were suppressed by Celecoxib (400 μg/ml) and Mesalazine (200 μg/ml).27 Therefore, Celecoxib and Mesalazine may be two good candidate drugs that could suppress a cytokine ‘storm,’ besides CsA.

Some people may argue that CsA is a typical immunosuppressive agent and may weaken the body’s resistance to AIV. However, considering that avian influenza causes an excessive immune response, it could be speculated that appropriately regulated immunity does not hamper the body’s normal resistance to AIV. In fact, CsA affects influenza A virus M1 protein and inhibits the nuclear export of viral mRNA, and subsequently inhibits virus replication.38

Previous studies reported that acute lung injury caused by chemical or microbial insults was secondary to the generation of host-derived, oxidized phospholipid that could potently stimulate Toll-like receptor 4 (TLR4)-dependent inflammation.39 A recent study has shown that the TLR4 antagonist Eritoran protects mice from lethal influenza infection.40 Eritoran is an alternative immunomodulator (besides CsA, Celecoxib, and Mesalazine, as mentioned above) for controlling the influenza-associated inflammation (Figure 3). Eritoran was originally designed as a drug for septicemia. The recent report showed that the survival rate of PR8 (a mouse-adapted influenza)-infected mice could reach 90% by the Eritoran treatment (if the mice were administered up to 6 days after influenza infection),40 indicating its strong

---

**Figure 2** Possible IR injury during clinical care of ARDS. (a) Normal ventilation–perfusion matching. (b) HPV. (c) Upon HPV, mechanical ventilation and high-flow oxygen therapy may restore the oxygen supply to the poorly ventilated alveolar cells (with the possible occurrence of IR injury). (d) Corticosteroid treatment and inhaled NO administration may restore the blood supply to the poorly ventilated alveolar cells (with the possible occurrence of IR injury). (e) Mismatching of blood flow and alveolar ventilation results in hypoxemia. (f) Upon a mismatch, mechanical ventilation and high-flow oxygen therapy may restore the oxygen supply to the poorly ventilated alveolar cells (with the possible occurrence of IR injury). (g) Upon a mismatch, corticosteroid treatment and inhaled NO administration may restore the blood supply to the poorly supplied but well-ventilated alveolar cells (with the possible occurrence of IR injury). (h) Cell death may ultimately result in ARDS care failure and organ death. CsA may inhibit this IR injury and alveolar damages.
immunomodulatory properties (may be stronger than all other immunomodulators). However, Eritoran has not been used formally clinically so far, and it has been observed that it may cause some notable side effects of a dose-dependent incidence of phlebitis.41 Similar to CsA, TLR4 also has a central role in IR injuries,42,43 which might suggest a similarity between AIV-induced inflammatory reactions and IR-mediated immune responses.

**Protectant of Lysosome Integrity**

Neutrophil lysosomes contain a variety of neutral proteases and acid proteases. When neutrophils are activated or destroyed, lysosome lysis occurs and the proteases are released, causing surrounding protein degradation and increasing alveolar/capillary membrane permeability.44 Thus, the elastase inhibitor has been considered for the AIV infection treatment, such as Sivelestat.44 However, Sivelestat is very expensive. The broad-spectrum protease inhibitor Ulinastatin, which also inhibits neutrophil elastase and lysosome lysis, may be used as an alternative selection.45,46 In H5N1-infected cells, the virus neuraminidase (NA) digests lysosomal membrane glycoproteins and affects lysosomal hydrolase, thereby undermining the integrity of the lysosome.47 Treatment with the protease inhibitor Ulinastatin could inhibit these destructive processes and could therefore be of potential importance to ARDS prevention and cure (Figure 3).

**Antiviral Drugs and the Others**

For AIV infection cure, suppression of viral replication or assembly has been adopted at the same time as well.48 NA inhibitors, such as Oseltamivir and Relenza (or called Zanamivir), are usually the first choice for AIV inhibition.1,2,48 Besides them, the other two licensed M2 ion-channel inhibitors, amantadine and rimantadine, are also used.49,50 Another NA inhibitor, peramivir (BioCryst Pharmaceuticals, Durham, NC, USA), was in phase 3 trials in 2009 for both intravenous and intramuscular routes of administration.51 Another long-acting NA inhibitor, designated CS-8958, was under study for use by inhalation, in Japan.52 The viral polymerase inhibitor T-705 (Favipiravir) was not only active against all three types of influenza virus (A, B and C) but also had some activity against other RNA viruses, including some of the hemorrhagic fever viruses.53,54 Sialidase fusion protein inhibitor DAS181 (Fludase) is a fusion construct that incorporates the sialidase from *Actinomyces viscosus*, a common oral bacterium linked to a human-epithelium-anchoring domain; it can be mass produced in *Escherichia coli*.55 The sialidase targets the viral attachment process, an early event in the replication of the influenza virus.55,56 Viral hemagglutinin inhibitors cyanovirin-N and thiazolides were also tested for H1N1 infection.57,58 Some new anti-influenza drugs have been developed recently, such as mechanism-based covalent NA inhibitors59 and Geldanamycin (an inhibitor of the viral polymerase assembly chaperone Hsp90).50,61 Moreover, combination therapy with currently available antivirals was supported by data from animal models and some clinical studies.

**Table 1** Licensed drugs for curing AIV infection and the complications

| Drug names                      | Classification/mechanism                                                             | Suggested applied occasion                                      | Possible side effects                                                                 |
|---------------------------------|--------------------------------------------------------------------------------------|----------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Vitamin C                       | Antioxidant                                                                          | The whole course (of the infection)                             | Diarrhea, nausea, vomiting and stomach cramps (high dose)                            |
| Cyclosporin A                   | Mitochondrial permeability protectant and immunosuppressant                          | Middle and advanced stages with the pulmonary symptom (may be especially useful after the ARDS care) | Renal tubular toxicity and vascular–interstitial lesions (only after long-term usage) |
| Celecoxib                       | Mitochondrial permeability protectant and immunosuppressant                          | Middle and advanced stages with the pulmonary symptom (may be especially useful after the ARDS care) | Diarrhea, dyspepsia, headache, respiratory infections, and so on                      |
| Mesalazine                      | Mitochondrial permeability protectant and immunosuppressant                          | Middle and advanced stages with the pulmonary symptom (may be especially useful after the ARDS care) | Headache, flatulence, hair loss and itching                                             |
| Sivelestat                      | Mitochondrial permeability protectant and immunosuppressant                          | The whole course                                               | No side effect observed                                                               |
| Ulinastatin                     | Mitochondrial permeability protectant and immunosuppressant                          | The whole course                                               | No side effect observed                                                               |
| Oseltamivir                     | Mitochondrial permeability protectant and immunosuppressant                          | The whole course                                               | No side effect observed                                                               |
| Relenza                         | Mitochondrial permeability protectant and immunosuppressant                          | The whole course                                               | No side effect observed                                                               |
| Amantadine                      | Mitochondrial permeability protectant and immunosuppressant                          | The whole course                                               | No side effect observed                                                               |
| Rimantadine                     | Mitochondrial permeability protectant and immunosuppressant                          | The whole course                                               | No side effect observed                                                               |

*Figure 3:* Model of the therapeutic mechanisms at the subcellular level. AIV-induced biochemical changes and cell death pathways are marked in red color. Potential targets of the drugs are marked in green color. AIV, avian influenza virus; Bcl-2, B-cell lymphoma 2; CAT, catalase; CsA, cyclosporin A; Cyt c, cytochrome c; MBCNI, mechanism-based covalent neuraminidase inhibitors; mPT, mitochondrial permeability transition; ROS, reactive oxygen species; SOD, superoxide dismutase; TNFα, tumor necrosis factor-α; VC, vitamin C
Conflict of Interest

The author declares no conflict of interest.
Drugs to cure avian influenza infection
S Yuan

29. Low IC, Kang J, Peruvaiz S. Bcl-2: a prime regulator of mitochondrial redox metabolism in cancer cells. Antioxid Redox Signal 2011; 15: 2975–2987.

30. Sun Y, Li C, Shu Y, Ju X, Zou Z, Wang H et al. Inhibition of autophagy ameliorates acute lung injury caused by avian influenza A(H5N1) infection. Sozial Med 2012; 5: r16.

31. Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin A and FKBP-FK506 complexes. Cell 1991; 66: 807–815.

32. Frantzi B, Nordby EC, Benc G, Steffen N, Paya CV, Malacarne P et al. Calcineurin acts in synergy with PMA to inactivate I kappa B/MAD3, an inhibitor of NF-kappa B. EMBO J 1994; 13: 881–887.

33. Grigoriu S, Bond R, Cospi A, Chen JA, Ly N, Hummer G et al. The molecular mechanism of substrate engagement and immunosuppressant inhibition of calcineurin. PLoS Biol 2013; 11: e1001492.

34. Millay DP, Sargent MA, Osinska H, Baines CP, Barton ER, Vuagniaux G et al. Genetic and pharmacological inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nat Med 2008; 14: 442–447.

35. Guo HK, Wang F, Yu QK, Chen J, Bai DL, Chen KX et al. Novel cyclophilin D inhibitors derived from quinoxaline exhibit highly inhibitory activity against rat mitochondrial swelling and Ca++ uptake/release. Acta Pharmacol Sin 2006; 27: 1201–1211.

36. Dandel M, Lehmkuhl HB, Krossa C, Hezner R. Impact of different long-term maintenance immunosuppressive therapy strategies on patients’ outcome after heart transplantation. Transpl Immunol 2010; 23: 93–100.

37. Szretter KJ, Gangappa S, Beiser JA, Zeng H, Chen H, Matsuoka Y et al. Early control of H5N1 influenza virus replication by the type I interferon response in mice. J Virol 2003; 77: 5826–5834.

38. Liu X, Zhao Z, Li Z, Xu C, Sun L, Chen J et al. Cyclophilin A inhibits the influenza virus replication through cyclophilin A-dependent and -independent pathways. PLoS One 2012; 7: e37277.

39. Imai Y, Kuba K, Neele GG, Yaghoubian-Mahamni R, Perkmann T, van Loo G et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 2008; 133: 235–249.

40. Shrey KA, Lai W, Scott AJ, Lipsky M, Mistry P, Pletneva LM et al. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature 2013; 497: 498–502.

41. Baba A, Solomon S, Cui X, Natanson C, Eichacker PQ. Eritoran tetrasodium (E5544) treatment for sepsis: review of preclinical and clinical studies. Expert Opin Drug Metab Toxicol 2011; 7: 479–494.

42. Shimamoto A, Pohlim TH, Shomura S, Tanukawa T, Takao M, Shimpoh L. Toll-like receptor 4 mediates lung ischemia-reperfusion injury. Ann Thorac Surg 2006; 82: 320–327.

43. Anumugam TV, Okun E, Tang SC, Thudiny J, Taylor SM, Woodruff TM. Toll-like receptors in ischemia-reperfusion injury. Shock 2009; 32: 4–16.

44. Iwata K, Doi A, Ohi T, Oka H, Oba Y, Takimoto K et al. Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): a systematic review and meta-analysis. Transpl Immunol 2010; 23: 93–100.

45. Kim JH, Resende R, Wennetek T, Ben H, Bucini S et al. Mechanism-based covalent immunosuppressant inhibitors with broad-spectrum influenza antiviral activity. Science 2013; 340: 71–75.

46. Chase G, Deng T, Fodor E, Leung BW, Mayer D, Schwemmle M et al. Hsp90 inhibitors reduce influenza virus replication in cell culture. Virology 2008; 377: 431–439.

47. Lu PP, Hu Y, Zhao BH, Zhong F, He HK. Galdenamycin reduces proliferation of highly pathogenic H5N1 avian influenza virus in vivo. Chin Sci Bull 2013; 58: 1021–1026.

48. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 2009; 48: 53–53.

49. Botz DA, Aldrich JR, Vargas C, Webster RG, Govorkova EA. Drugs in development for influenza. Drugs 2010; 70: 1349–1362.

50. Weitzen RS. Glucocorticoid-induced osteonecrosis. Endocrine 2012; 41: 183–190.

51. DeMing RH. The modern version of adult respiratory distress syndrome. Annu Rev Med 1995; 46: 193–202.

52. Matthews MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome. J Clin Invest 2012; 122: 2731–2740.

53. Hu Y, Lu S, Song Z, Wang W, Hao P, Li J et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013; 381: 2273–2277.

54. Koinuma D, Miki M, Ebina M, Tahara M, Hagisawa K, Kondo T et al. Successful treatment of a case with rapidly progressive Bronchiolitis obliterans organizing pneumonia (BOOP) using cyclosporin A and corticosteroid. Intern Med 2002; 41: 26–29.

55. Caliendo AM, Hirsch MS. Combination therapy for infection due to human immunodeficiency virus type 1. Clin Infect Dis 1994; 18: 516–524.

56. Levy GA. C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation. BioDrugs 2001; 15: 279–290.

57. Barbaro D, Orsini P, Pallini S, Piazza F, Pasquali C. Obesity in transplant patients: case report showing interference of orlistat with absorption of cyclosporine and review of literature. Endocr Pract 2002; 8: 124–126.

58. Federico S, Carrano R, Capone D, Gentile A, Palmiero G, Basile V. Pharmacokinetic interaction between levofloxacin and ciprofloxacin or tetracikin in kidney transplant recipients: ciprofloxin, tetracikin and levofloxacin in renal transplantation. Clin Pharmacokinet 2004; 45: 169–175.